Isabella Ciccone, assistant editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter at @iciccone7 or email her at firstname.lastname@example.org.
Racial Disparities in Acute Care Utilization Seen Among Patients With Myasthenia Gravis
Research presented at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting emphasizes the potential need for patient support programs targeting at-risk populations to enhance disease management and reduce acute care utilization in myasthenia gravis.
FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis
The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Phase 1/2 Findings Highlight RGX-202’s Safety, Impact on Key Duchenne Biomarkers
RGX-202, a gene therapy for Duchenne muscular dystrophy, was well tolerated with no therapy-related serious adverse effects in 3 patients who received the level 1 dosage.
Subanalysis of ADAPT Reveals Consistent Efficacy With Efgartigimod Among All Genders
Patients with generalized myasthenia gravis treated with efgartigimod consistently exceeded treatment compared with placebo regardless of gender in age, disease duration, body mass index, and thymectomy.
Autonomic Dysfunction Significantly Associated With Decreased Quality of Life in MS, NMOSD
Findings showed that autonomic symptom burden was slightly more severe in patients with multiple sclerosis (MS) compared with those with NMOSD, although the difference was not statistically significant.
Memory Consolidation in Epilepsy Enhanced During Sleep With Deep Brain Stimulation
Researchers developed a novel “closed-loop” system that delivered electrical pulses in a brain region to synchronize brain activity recorded from another region in the brain to improve memory.
Generalized Myasthenia Gravis Symptom Severity Reduced Through Ravulizumab Treatment
The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks.
Zilucoplan Demonstrates Consistent Efficacy in Phase 3 RAISE Study of Generalized Myasthenia Gravis
Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.
A Balancing Challenge: Social Relationships in the Life of Adolescents With Narcolepsy
Anne Marie Morse, DO, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, talked about the challenges that adolescents with narcolepsy face in their social relationships.
2 Clarke Drive Cranbury, NJ 08512